eXmoor Pharma secures contract to work with New Zealand Blood Service

18 January 2021: eXmoor Pharma, experts in strategic and technical biomanufacturing, specialising in cell and gene therapy, has signed a deal to work with the New Zealand Blood Service (NZBS).

Bristol-based eXmoor, which has worked in over 15 countries worldwide, will be providing NZBS with valuable Quality support as they build and establish a new site near Auckland.

The eXmoor UK team will be advising NZBS on the GMP (Good Manufacturing Practice) aspects of its proposed new build ATMP (advanced therapy medicinal products) facility based in Highbrook, New Zealand. They will provide GMP oversight over an initial four-month engagement with a view to longer term support.

This will be eXmoor’s first project in the Australasia region. The UK-based delivery team has adapted its working processes to allow for collaborative communication across time zones with the NZBS team.

This deal comes on the back of the work which eXmoor has undertaken in the UK for NHS Blood &Transplant (NHSBT) .

eXmoor GMP Compliance Consultant, Rob Scott who will lead this project has provided QP services to NHSBT to release batches of product; the firm has worked with the Filton, Bristol-based Clinical Biotechnology Centre since 2017.

Angela Osborne, CEO, eXmoor Pharma commented: “We are delighted to be working with NZBS. We have specific experience in supporting the manufacture of ATMPs having designed 32 manufacturing facilities and supported over 125 clients across more than 400 projects in the advanced therapies and biopharmaceutical sector.

“This facility is important to the future success and operation of NZBS and we are looking forward to building a long-term, collaborative relationship with their team.”

Fidelma Murphy, Director, Quality and Regulatory Affairs and Privacy Officer for New Zealand Blood Service, said: “I am pleased to be working with the eXmoor team. Their experience is unparalleled and the expertise and oversight they are providing will ensure the facility we develop and the way we operate for many years to come.”

This latest contract win for eXmoor comes off the back of the major £12m investment the firm announced earlier this year from healthcare investment firm MVM. It is currently working towards expansion into the North American market and will also be opening its own dedicated 50,000 ft2 CGT process development and clinical manufacturing facility in Bristol (UK) in 2022.

 


More news and updates

Data from Brainomix’s Collaboration with AstraZeneca Shows its AI-Powered e-Lung Better Identifies Lung Fibrosis Patients at Risk of Decline

Brainomix and AstraZeneca partnered to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients, leveraging Brainomix’s AI-powered e-Lung software and biomarkers to uncover novel insights. Published data shows e-Lung could play a role in stratifying patients in clinical trials most at risk of decline, outperforming current standard measures.

Eight things we learned about commercialising medical research at Imperial's 'All You Can Innovate' 2024

Why to channel Scottish polymath Mary Somerville, how timing can make or break a startup, and other lessons from experts at All You Can Innovate 2024.

PrecisionLife and NATA announce R&D partnership to jointly develop new motor neurone disease

Leading precision medicine and nucleic acid therapy (NAT) innovators will harness their platforms to develop NAT drug candidates for novel gene targets with strong genetic association to sporadic ALS. The programme will be supported by mechanism-based patient stratification biomarkers to identify likely responders and accelerate and derisk clinical development.

 

More within